Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD
Status:
Completed
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
Patients with refractory or relapsed acute myeloid leukemia (AML) after two courses of
standard chemotherapy regimens have very limited options. Further chemotherapy is associated
with significant toxicity and is generally ineffective. About 10-30% patients with AML carry
a gain-of-function mutation of a gene known as Flt3 in the leukemic cells, conferring them
with abnormal cellular proliferation. Sorafenib is a multi-kinase inhibitor which was
licensed in Hong Kong for the treatment of advanced hepatocellular and renal cell carcinoma.
The drug has also been shown to be effective against Flt3 and AML but it has not been
licensed for use in this condition.